Sir Paul Callaghan s Vision deeply Considered As Kiwi Landing Pad Reimagines Its Purpose scoop.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scoop.co.nz Daily Mail and Mail on Sunday newspapers.
.
If your child has ever suffered from a painful earache, and that includes most parents, you’ll be delighted to hear about PhotoniCare.
The Champaign, Illinois startup recently expanded to North Carolina, where it has set up shop at the North Carolina Biotechnology Center’s Landing Pad.
PhotoniCare has received U.S. Food and Drug Administration clearance to market its OtoSight Middle Ear Scope. OtoSight is a patented hand-held device that uses near-infrared light waves (optical coherence tomography, or OCT) to provide a uniquely important view of the tissue of the middle ear behind the eardrum.
The device allows medical practitioners to more-accurately determine the presence or absence of fluid in the middle ear and visualize the type of fluid causing the ear infections that plague more than 80% of children. These infections are a leading cause of hearing loss, surgery and antibiotic use.
In early January, Eric Jaenike and Jennifer Mosquera of immersive-arts duo Prismajic met over drinks with Amber Blais and Staza Stone of circus-arts troupe Rainbow Militia. Both groups had spent the past few years pushing the boundaries of immersive arts in Denver and were mutual admirers of each other s work. They started talking about how they might collaborate, and it didn t take long before they settled on an idea: a performance set in the clouds and rooted in Greek mythology.
During the meeting, Jaenike and Mosquera conjured up images of clouds, lighting, starlight and an idyllic cabin in the woods. “Amber and I left that meeting and came up with the entire plot and storyline, says Stone.
by Frank Vinluan, NCBiotech writer December 21, 2020 .
RESEARCH TRIANGLE PARK – Heat Biologics, a clinical-stage immunotherapies developer, is moving closer to human testing of a vaccine for COVID-19.
The Morrisville-based biotech reported preclinical data showing that its vaccine candidate, ZVX-60, prompted the expression of two proteins key to an immune response. The Heat vaccine also led to the expression of the “spike protein” characteristic of the novel coronavirus.
Heat develops drugs that activate T-cells and gets them to proliferate, mounting an immune response to disease. The company’s technology platform is the basis for drugs that employ gp96, a “heat shock” protein that activates a T-cell immune response. The company’s lead drug candidate, a cell therapy code-named HS-110, is currently in mid-stage testing as a treatment for non-small cell lung cancer.